Bin‐Yan Zhong

Transarterial chemoembolization (TACE) combined with immunotherapy and anti-angiogenic agents in intermediate-stage hepatocellular carcinoma (CHANCE2202): a target trial emulation study

Camrelizumab and Apatinib With or Without Transarterial Chemoembolisation as First‐Line Treatment for Advanced Hepatocellular Carcinoma

Combination locoregional and systemic therapies in hepatocellular carcinoma

Decoding tumor heterogeneity with imaging biomarkers predicts response to TACE plus immunotherapy and targeted therapy in HCC (CHANCE2204)

Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study

Transarterial chemoembolization for hepatocellular carcinoma: Treatment algorithm proposed by Chinese College of Interventionalists (CCI)

Locoregional therapies for hepatocellular carcinoma: The current status and future perspectives

Longitudinal Body Composition Identifies Hepatocellular Carcinoma With Cachexia Following Combined Immunotherapy and Target Therapy (CHANCE2213)

Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)

Transarterial Chemoembolization for Patients with Unresectable Hepatocellular Carcinoma with Child-Pugh B7

Clinical practice of transarterial chemoembolization for hepatocellular carcinoma: consensus statement from an international expert panel of International Society of Multidisciplinary Interventional Oncology (ISMIO)

Deep Learning Predicts Overall Survival of Patients With Unresectable Hepatocellular Carcinoma Treated by Transarterial Chemoembolization Plus Sorafenib

Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west